Leah Kuntz

Join us in congratulating Dr Tampi on his recent win of the American Association for Geriatric Psychiatry’s Diversity Award!

A new study found that when glucose is either very high or low in patients with type 1 diabetes, cognition is slower; however, slightly above average glucose led to peak cognitive performance.

Pimavanserin failed to achieve the primary efficacy endpoint of control of negative symptoms in patients with schizophrenia in the ADVANCE-2 trial. Acadia Pharmaceuticals will not pursue further research.

New research on transcranial direct current stimulation effectiveness in treating major depressive disorder.

Alzheimer disease treatment donanemab will be delayed as the FDA plans to convene a committee meeting to evaluate the phase 3 Trailblazer-Alz 2 trial.

The US Food and Drug Administration has granted breakthrough designation to MindMed’s lysergide d-tartrate program (MM-120) for the treatment of generalized anxiety disorder.

Psychiatric Times highlighted takeaways from the 2023 American College of Neuropsychopharmacology Annual Meeting in our February issue. Don't miss out on these important conference clinical pearls!

Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

AVP-786, a drug to treat agitation associated with Alzheimer disease dementia, failed to meet the primary efficacy endpoint in a phase 3 clinical trial.

Learn more about the inaugural Black Youth Mental Health Clinical Case Conference Series at Yale Child Study Center, a 6-session event in 2024, that focuses on improving mental health care for Black youth and their families.

New positive data on TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

New research finds whole-family collaborative care digital mental health interventions help manage disordered eating behaviors in adolescents aged 13-17.

Frank Clark, MD, the Psychiatric Times Diversity & Inclusion Section Editor, was recently appointed president of The Greenville County Medical Society, the first Black doctor to serve in this role.

Biogen has officially announced its decision to discontinue all development and sales of aducanumab (Aduhelm) for Alzheimer disease.

The FDA granted clearance for a transcranial magnetic stimulation technology indicated for major depressive disorder and obsessive-compulsive disorder.

This APSARD 2024 conference poster finds that individuals with ADHD have distinct motivations and patterns of substance use.

New positive pivotal phase 3 study data released on oral weekly risperidone for schizophrenia.

New study results show evenamide as an add-on to antipsychotics for treatment-resistant schizophrenia significantly reduced disease severity.

Did you miss the 2023 Annual Psychiatric Times World CME Conference? Don't worry, we've got you covered.

MAPS has submitted an NDA for MDMA-assisted therapy for patients with posttraumatic stress disorder.

These important findings on esketamine nasal spray as a treatment for young individuals with suicidal ideation were presented at the ACNP 2023 Annual Meeting. We interviewed the vice president and head of neuropsychiatry clinical development at Johnson & Johnson Innovative Medicine to learn more.

What neuromodulation can be used to specifically target nicotine users with schizophrenia? This research may tell us.

This ACNP 2023 Annual Meeting poster covered a 26-week study on cariprazine as an adjunctive treatment to antidepressants in patients with major depressive disorder.

Neurosteroid therapeutics could be the solution to provide fast-acting treatment for mothers with postpartum depression.

Check out these brief summaries on cognitive impairment in schizophrenia from an excellent session at the ACNP 2023 Annual Meeting!

DBS in psychiatry: What challenges stand between this treatment and success? Alik Widge, MD, PhD, shares more at the ACNP 2023 Annual meeting.

Did you catch the President's Plenary at the ACNP 2023 Annual Meeting?

Navacaprant—a novel, oral, once-daily, highly selective kappa opioid receptor antagonist that is currently in phase 3 development as a monotherapy for major depressive disorder.

It is Transgender Awareness Week. Here’s what you need to know as a clinician.

New positive data for brexpiprazole, the first and only treatment approved to treat agitation associated with dementia due to Alzheimer disease.